Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Malays J Pathol ; 45(1): 31-41, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37119244

ABSTRACT

INTRODUCTION: The treatment of Plasmodium vivax malaria with 8-aminoquinolines is contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals due to the risk of acute haemolytic anaemia. Effective G6PD screening is paramount to avoid adverse drug reactions. This study aimed to evaluate the performance of novel quantitative point-of-care (POC) tests as a new screening method for G6PD deficiency in Malaysia. MATERIALS AND METHODS: A total of 153 neonatal cord blood, 99 peripheral blood of older children aged between 1 month to 12-years old, and 62 peripheral adult blood were screened for G6PD deficiency using two quantitative POC tests, CareStartTM biosensor (Carestart) and CareStartTM Biosensor 1 (S1). The results were compared with OSMMR2000D kit as a reference assay. Two statistical analyses were performed in this study to evaluate the POC test performances, the Spearman's correlation test and the Cohen's kappa method. RESULTS: Both Carestart and S1 tests showed significant positive correlations to OSMMRS000D with r2 = 0.7916 and r2 = 0.7467. Their measurement of agreement showed a kappa (κ) value of 0.805 (p<0.001, 95% CI), and 0.795 (p<0.001, 95% CI), respectively. Analysis of the area under the Receiver Operating Curve (ROC) at 60% cut-off illustrated that the Carestart had 90.2% sensitivity, 98.9% specificity, 98.3% positive predictive value (PPV), and 93.8% negative predictive value (NPV). The corresponding values for the S1 were 95.2%, 100%, 100%, and 96.8%, respectively. CONCLUSION: This study showed that the Carestart and S1 biosensors have high-performance reliability for screening of G6PD deficiency, which can guide safe prescriptions of anti-malaria medications and hence, eradication of Plasmodium vivax malaria.


Subject(s)
Glucosephosphate Dehydrogenase Deficiency , Malaria, Vivax , Adult , Child , Infant, Newborn , Humans , Adolescent , Infant , Glucosephosphate Dehydrogenase Deficiency/diagnosis , Glucosephosphate Dehydrogenase/therapeutic use , Malaria, Vivax/diagnosis , Malaria, Vivax/drug therapy , Reproducibility of Results , Malaysia , Point-of-Care Testing
2.
Heart ; 90(4): e18, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15020536

ABSTRACT

Prosthetic valve thrombosis (PVT) is classically a cardiothoracic surgical emergency. Case series, however, report thrombolysis as first line management for PVT. A case of mitral PVT treated successfully with thrombolysis is described. Immediately after thrombolysis a trivial paraprosthetic leak noted on pretreatment transoesophageal echocardiography had increased significantly in severity. The paraprosthetic leak subsequently required repeat mitral valve replacement. It is speculated that the thrombolytic treatment interfered with the usual healing process by disrupting the fibrin deposited at the valve ring margin. This suggests that fibrin is important in the formation of the annular seal of the prosthetic valve and that patients receiving thrombolysis should be monitored for this complication.


Subject(s)
Mitral Valve Insufficiency/chemically induced , Mitral Valve Stenosis/drug therapy , Mitral Valve , Thrombolytic Therapy/adverse effects , Thrombosis/drug therapy , Aged , Anticoagulants/adverse effects , Echocardiography, Transesophageal , Fibrinolytic Agents/adverse effects , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation , Humans , Male , Mitral Valve Insufficiency/diagnostic imaging , Mitral Valve Insufficiency/surgery , Mitral Valve Stenosis/diagnostic imaging , Prosthesis Failure , Recurrence , Reoperation , Thrombosis/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...